Close Menu

commercialization agreement

Seer will be able to offer its Proteograph Product Suite for sale with several of the two companies' mass spectrometers.

The test will identify more than 100 pathogens, as well as drug resistance in viruses and bacteria.

The partners will commercialize a line of oncology mutation panels on the Stilla Naica digital PCR system.

The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.

FASMAC provides food analysis and biotech products and services, including DNA/RNA synthesis, DNA sequencing, food testing, and genetic analysis reagents.

BillionToOne's assay detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day.

Applied StemCell, based in the San Francisco Bay Area, will develop and sell CRISPR-based services and reagents under a license from ERS Genomics.

HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.

OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.

Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK. 

Pages

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.